Riskpilot← Back to searchSign inGet full accessBIOMOTION PHARMA ApS
APSIn liquidationCVR 12928203Stockholmsgade 37, 3. tvWholesale of pharmaceutical and medical goods · NACE 4646Est. 1989— employees
Revenue 2024
DKK -5K
EBITDA margin
100.0%
-272% vs 2023
Equity ratio
42.4%
Financial strength
Net profit 2024
DKK -6K
-352% vs 2023
| Revenue | DKK -5K | — |
| EBITDA | DKK -5K | -272% |
| Net profit | DKK -6K | -352% |
| Total assets | DKK 8K | -29% |
| Equity | DKK 3K | -66% |
| Employees | — | — |
Legal name
BIOMOTION PHARMA ApS
CVR number
12928203
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. april 1989
Share capital
DKK 125.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2024-09-30
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Company purpose
Selskabets formål er at drive virksomhed indenfor handel produktion, service og investering samt hermed beslægtede aktiviteter
Address
Stockholmsgade 37, 3. tv
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | -1 | 3 | 0 | — | 5 | -2 | -1 | -1 | 16 | 0 | -5 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 3 | 3 | -1 | 3 | 0 | 0 | 5 | -2 | -1 | -1 | 6 | -1 | -5 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 3 | 3 | -1 | 3 | 0 | 0 | 5 | -2 | -1 | -1 | 6 | -1 | -5 |
| Net financials | 0 | 0 | 0 | -5 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | -1 |
| Profit before tax | 3 | 3 | -1 | -2 | 0 | 0 | 5 | -2 | -1 | 4 | 6 | -1 | -6 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | 3 | 3 | -1 | -2 | 0 | 0 | 5 | -2 | -1 | 4 | 6 | -1 | -6 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 3 | 2 | 0 | 0 | 0 | 5 | 4 | 3 | 6 | 12 | 11 | 8 |
| Equity | -1 | 2 | 1 | -1 | -1 | -1 | 4 | 3 | 1 | 5 | 11 | 10 | 3 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
| Total debt | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 |
EBITDA margin
-531300.0%
This company
15.8%
Market median
-3362758% vs market
20122024
Equity ratio
42.4%
This company
38.2%
Market median
+11% vs market
20122024
Return on equity
-195.2%
This company
18.4%
Market median
-1161% vs market
20122024
Net profit margin
-646000.0%
This company
8.1%
Market median
-7975409% vs market
20122024
Asset turnover
-0.68×
This company
1.12×
Market median
-161% vs market
20122024
Debt / equity
1.36×
This company
0.62×
Market median
-119% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
ET | Audit | 1989 | — | — |
MA Management | Management | 1989 | — | — |
LR Management | Management | 1989 | — | — |
PE Management | Management | 1989 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 1996 | — | — | |
| Board of Directors | 1989 | — | — | |
| Board of Directors | 1989 | — | — | |
| Board of Directors | 1989 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2012 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BIOMOTION PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Tronborg Andersen | Audit | 0 companies |
| Michael Alstrøm | Management | 0 companies |
| Lennie Rasmussen | Management | 0 companies |
| Per Emil Hasselbalch Stakemann | Management | 0 companies |
| Anne Lyngholm | Board of Directors | 0 companies |
| Preben Elkjær Larsen | Board of Directors | 0 companies |
| Annette Overgaard Hansen | Board of Directors | 0 companies |
| Inga Hansen | Board of Directors | 0 companies |